Research graph
References from Kidney function decline, heart failure hospitalization, and the effect of empagliflozin in heart failure: an EMPEROR-pooled analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology
10.1002/ejhf.1697 · 2020 · External reference
Association of estimated GFR slope and heart failure progression in older adults
10.1053/j.ajkd.2025.01.011 · 2025 · External reference
Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements (SCREAM) project
10.1002/ejhf.1968 · 2020 · External reference
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction
10.1093/eurheartj/ehaf457 · 2025 · External reference
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial
10.1002/ejhf.2638 · 2022 · External reference
A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: a scientific statement from the American Heart Association
10.1161/cir.0000000000001186 · 2023 · External reference
Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: a comprehensive French nationwide cohort study
10.1093/ndt/gfac153 · 2022 · External reference
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study
10.1093/eurheartj/ehac825 · 2023 · External reference
Cardiovascular and renal outcomes with empagliflozin in heart failure
10.1056/nejmoa2022190 · 2020 · External reference
Empagliflozin in heart failure with a preserved ejection fraction
10.1056/nejmoa2107038 · 2021 · External reference
Dapagliflozin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa1911303 · 2019 · External reference
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
10.1056/nejmoa2206286 · 2022 · External reference
Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF
10.1161/circulationaha.120.050391 · 2021 · External reference
Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial
10.1001/jamacardio.2022.4210 · 2023 · External reference
Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
10.1002/ejhf.2065 · 2020 · External reference
Empagliflozin and major renal outcomes in heart failure
10.1056/nejmc2112411 · 2021 · External reference
A new equation to estimate glomerular filtration rate
10.7326/0003-4819-150-9-200905050-00006 · 2009 · External reference
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced
10.1002/ejhf.2578 · 2022 · External reference
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved
10.1002/ejhf.3136 · 2024 · External reference
Renal compression in heart failure: the renal tamponade hypothesis
10.1016/j.jchf.2021.12.005 · 2022 · External reference
Cardiac congestion assessed by natriuretic peptides oversimplifies the definition and treatment of heart failure
10.1002/ehf2.13495 · 2021 · External reference
Cardiorenal syndrome revisited
10.1161/circulationaha.117.028814 · 2018 · External reference
Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
10.1016/j.jchf.2026.102943 · 2026 · External reference
Urinary markers in heart failure—types, timing and thresholds. European Journal of Heart Failure Expert Consensus Document
10.1002/ejhf.70079 · 2025 · External reference
Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial
10.1681/asn.2018010103 · 2018 · External reference
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · 2023 · External reference
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
10.1016/s2213-8587(21)00242-4 · 2021 · External reference
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
10.1016/s2213-8587(19)30180-9 · 2019 · External reference
Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis
10.1161/circulationaha.122.061732 · 2022 · External reference
SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback
10.34067/kid.0000000000000425 · 2024 · External reference
Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial
10.1093/ckj/sfy122 · 2019 · External reference
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
10.1002/ejhf.2874 · 2023 · External reference
Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week
10.1016/j.jacc.2022.11.023 · 2023 · External reference
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
10.1038/s41591-021-01659-1 · 2022 · External reference
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
10.1002/ejhf.2681 · 2022 · External reference
Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
10.1002/ejhf.2620 · 2022 · External reference
Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease
10.1093/eurheartj/ehaf225 · 2025 · External reference
Burden of chronic kidney disease and outcomes following hospitalisation for heart failure
10.1136/heartjnl-2025-327053 · 2026 · External reference
Sodium-glucose cotransporter 2 inhibitor use for heart failure in US ambulatory cardiovascular care
10.1001/jamacardio.2025.2145 · 2025 · External reference
Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction
10.1001/jamacardio.2024.4489 · 2025 · External reference
Trends in the use of sodium-glucose cotransporter-2 inhibitors and characteristics of adverse event reporting in patients with heart failure in Japan: reports from the medical administration database and the adverse event reporting database
10.1080/14740338.2025.2539543 · 2025 · External reference
